62 results about "Mechanical pain" patented technology

The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.

The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.

A restraint and exercise device is provided to treat acute or chronic mechanical pain, particularly lumbopelvic and / or leg pain, and to restore and / or increase range of motion in suitable users. The device is particularly useful during exercise. The device may contain a restraint, such as two straps, connected to a support structure. The straps help restrain a portion of a person's body such as the pelvic region. The portion of the person's body may be restrained in a substantially pain-free position so as to reduce the pain that would otherwise be felt during exercise.

A restraint and exercise device is provided to treat acute or chronic mechanical pain, particularly lumbopelvic and / or leg pain, and to restore and / or increase range of motion in suitable users. The device is particularly useful during exercise. The device may contain a restraint, such as two straps, connected to a support structure. The straps help restrain a portion of a person's body such as the pelvic region. The portion of the person's body may be restrained in a substantially pain-free position so as to reduce the pain that would otherwise be felt during exercise.

A restraint and exercise device is provided to treat acute or chronic mechanical pain, particularly lumbopelvic and / or leg pain, and to restore and / or increase range of motion in suitable users. The device is particularly useful during exercise. The device may contain a restraint, such as two straps, connected to a support structure. The straps help restrain a portion of a person's body such as the pelvic region. The portion of the person's body may be restrained in a substantially pain-free position so as to reduce the pain that would otherwise be felt during exercise.

The invention relates to a Chinese medicine composition for treating ischemic necrosis of femoral head, which solves the problems that the western medicine only releases pain, the Chinese medicine has long treatment period and slow effect, and the operation treatment has large risk and high cost as well as easy recrudescence. The Chinese medicine composition is prepared by the following raw materials according to the weight proportion: 10-100g of angelica, 20-50g of corydalis tuber, 20-60g of heracleum hemsleyanum michaux, 20-40g of frankincense, 20-40g of myrrh, 10-50g of angelica dahurica, 20-50g of cinnamon, 30-100g of rhizoma drynariae, 20-60g of radix dipsaci from Sichuan of China, 20-50g of rhizoma cibotii, 40-100g of lopseed, 20-50g of dragon's blood and 10-50g of eupolyphage sece steleophaga. The Chinese medicine composition has short treatment period and rapid effect, can eliminate the ischemic necrosis of femoral head and the inflammatory pain of rachitis, can eliminate mechanical pain of cervical vertebra and lumbar intervertebral disc protrusion, can repair fiber ring scission, builds the health, improves the microcirculation without side and toxic effects, and promotes the sequestrum absorption of the ischemic necrosis of femoral head and the regeneration of the bone trabecula, thereby achieving the purpose of addressing both the symptoms and root causes.

The invention discloses a mechanical pain sensitivity measurement instrument, which comprises a shell, wherein a rotary handle, which is capable of rotating in a circumferential direction of the shell, is arranged on the tail of the shell; a rotary tray, which is capable of synchronously rotating along with the rotary handle, is arranged in the shell; the side, facing the front end of the shell, of the rotary tray is provided with a plurality of base inserting holes in the circumferential direction; a measurement wire fixing base is inserted in each base inserting hole, and a measurement wire, which is used for detecting mechanical pain, is arranged at the front end of each measurement wire fixing base; strip-shaped holes are formed in the shell in a length direction; and a clamping piece, which is capable of clamping the measurement wire fixing bases and drawing the measurement wire fixing bases out of the base inserting holes, is additionally arranged on the shell. The mechanical pain sensitivity measurement instrument provided by the invention is mainly used for assessing skin mechanical pain tests; as a non-injury tool for assessing a skin mechanical pain degree, the measurement instrument, when applied to pain tests on a patient, can be used for testing a pain threshold and a pain range of the patient relatively precisely, and an accurate and practical effect can be achieved in a using process.

A restraint, reposition, traction, and exercise device treats acute or chronic mechanical pain, particularly back, neck, hip, pelvis, shoulder, knees, and / or leg pain, and restores and / or increases range of motion in suitable users. The device may include two or more movable support structures and two or more restraints, such as straps. The restraints may be incrementally adjustable to stabilize two or more portions of a person's body, such as the back and / or pelvic regions, against the support structures in any number of three-dimensional orientations that produce a substantially pain-free position. The support structures may be moved apart to apply spinal traction to the portions of the person's body between the restraints. Exercises may be performed while in a substantially pain-free position before, during, or after spinal traction is applied. The user may reposition and restrain herself / himself in another substantially pain-free position and then re-apply spinal traction and / or perform further exercises.

A composition having sustained pain-relieving properties such that the composition may be administered to a subject to alleviate chronic pain. The composition includes an effective amount of at least one glutaminase inhibitor. A method for alleviating chronic pain in a subject for an extended period of time is also disclosed, in which the compound is administered to a subject suffering from chronic pain at a site of inflammation such that the administration of the compound results in a reduction in at least one of thermal and mechanical pain responses at the site of inflammation for a period of at least two days without any resulting acute pain behavior. The composition may further include an effective amount of at least one compound having analgesic effects such that the composition also alleviates acute pain.

The invention relates to a sciatic nerve ligation subcutaneous tumor-bearing rat model and application of the sciatic nerve ligation subcutaneous tumor-bearing rat model in screening of analgesic and anti-tumor medicine. Single-side sciatic nerve ligation is conducted on an adult Wistar rat subjected to hypodermic implantation of Walker256 tumor cell suspension, the pain degree of the rat is reflected through spontaneous pain, the mechanical pain threshold value and the hot pain threshold value, and the tumor growth situation is indicated through the body weight change, the tumor formation rate and the tumor size of the rat. After the to-be-detected medicine is applied to the animal model according to the required mode and dosage, and the effect of the to-be-detected medicine on the aspect of analgesia and tumor prevention is judged by observing changes of the indexes. The experimental animal model which has the lasting and stable pain characteristic and can visually measure the tumor growth situation of the tumor of the rat is used for exploring the mechanism of promoting tumor growth through pain and used for screening the novel analgesic and anti-tumor medicine. The new carrier is provided for research and development of the novel analgesic and anti-tumor medicine.

The invention discloses a mechanical pain sensitivity measurement device, which comprises a shell, wherein a plurality of measurement wires, which are used for detecting mechanical pain, are arranged in the shell; a plurality of measurement wire outlet holes are formed in the front wall of the shell; a plurality of measurement wire popping mechanisms, by which the measurement wires prop out of the shell, are arranged in the shell; and return plates, by which the popped measurement wires are withdrawn into the shell, are additionally arranged in the shell. According to the measurement device disclosed by the invention, touch test skin can be stimulated; the measurement device is simple to operate, and a user can automatically record a pain threshold and conveniently and rapidly conduct a relatively comprehensive test on surface pain and intrinsic referred pain of a patient. The mechanical pain sensitivity measurement device provided by the invention is mainly used for assessing skin mechanical pain tests; the mechanical pain sensitivity measurement device, as a non-injury tool for assessing a mechanical pain degree of skin, is applicable to pain tests of the patient and is capable of testing the pain threshold and a pain range of patient relatively precisely; and in addition, effects of being accurate and practical can be achieved in a using process.

A composition having sustained pain-relieving properties such that the composition may be administered to a subject to alleviate chronic pain. The composition includes an effective amount of at least one inhibitor of neurotransmitter synthesis. A method for alleviating chronic pain in a subject for an extended period of time is also disclosed, in which the compound is administered to a subject suffering from chronic pain at a site of inflammation such that the administration of the compound results in a reduction in at least one of thermal and mechanical pain responses at the site of inflammation for a period of at least two days without any resulting acute pain behavior. The composition may further include an effective amount of at least one compound having analgesic effects such that the composition also alleviates acute pain.

The invention relates to spider polypeptide toxin with a Nav1.9 specific activation effect. The spider polypeptide toxin controls a sodium channel subtype Nav1.9 through a specific activation of a voltage gate, so as to recover the pain feeling of a patient with pain insensitivity. Experiments prove that HpTx1 is unique to other channels for enhancing the Nav1.9 function, and animal experiments show that the spider polypeptide toxin can enhance related congenital painless pain behaviors caused by Nav1.7 loss and recover mechanical pain sensitivity and the like, so that clinical application totreat pain insensitivity diseases, especially congenital painless diseases related to Nav1.7. Therefore, the invention also provides an application of the polypeptide toxin in preparation of a medicine for treating congenital pain deficiency, especially an application in preparation of a medicine for treating Nav1.7 related congenital painless diseases. In addition, the HpTx1 is a good Nav1.9 channel tool reagent.

The invention discloses an application of trifluoroicaritin in preparation of a medicine for improving pain, swelling and movement functions. The application of the trifluoroicaritin in the medicine for treating the chronic inflammatory pain proves that the trifluoroicaritin can effectively relieve mechanical pain sensitivity and heat pain sensitivity of the chronic inflammatory pain, improve thetissue swelling degree and the movement function of the chronic inflammatory pain, up-regulate the protein and mRNA level of alpha7nAChR and IL-10 and down-regulate the protein and mRNA level of HMGB1, p-NF-kappaB (p-P65) and IL-1beta. Therefore, the trifluoroicaritin is a medicine which has development potential and is used for treating chronic inflammatory pain.

The invention relates to an inclined plate type mechanical pain-sensitivity determining device which adopts the structure that the bottom side of a vertical plate is vertical to a horizontal plate; the horizontal plate and an inclined plate positioned above the horizontal plate are rotatably connected through a shaft lever; a wire mesh is arranged in the middle of the inclined plate; a magnet is positioned below the wire mesh, a probe is arranged on the magnet and extends out of the wire mesh; angle measuring scales are radially marked on the vertical plate from the left bottom corner to the right top corner. According to the invention, the defects in the prior art that the price is expensive, users are easy to suffer from cervical vertebra strain, the probe is easy to damage, and the pain-sensitivity threshold value of the bottom of only one paw can be determined once are overcome; the determining device has the advantages that the manufacture is simple; angle is used for grading pain degrees, can be directly used as a comparison parameter, and can be converted into force F for comparison according to the formula: F=0.25mgcos alpha, so that the determination accuracy is good; through the measurement of the weight of rats, the paw withdrawal mechanical threshold (the probe irritation force F) of rats can be accurately calculated; therefore, the determining device is applicable to the determination of mechanical pain threshold values of big and small animals.

The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.

The invention discloses an application of short peptide in the preparation of a product with a morphine tolerance eliminating effect. Researches find that short peptide P10581 can basically and completely turn over an inflammatory pain threshold value induced by carrageenan, and the analgesic effect lasts for more than 12 hours, which indicates that short peptide P10581 has no tolerance to the analgesic effect of mechanical pain, and the tolerance of the analgesic effect of morphine can also be eliminated by the low-dose synthetic short peptide P10581.

The invention belongs to the technical field of biology, and relates to application of a Walker256 ascites tumor cell in preparing a bone cancer pain model. The bone cancer pain model comprises a calcaneus cancer pain or osteitis pain model. In the invention, ethological index tests including radiation heat pain threshold variations, mechanical pain threshold variations and other related indexes are carried out on the prepared calcaneus cancer pain model or osteitis pain model, and the result indicates that the ethological indexes of the experimental animal do not have obvious variations. The bone cancer pain model prepared by the invention provides a valuable experimental research tool and platform for researching the bone cancer pain mechanism, evaluating the analgesic effect of medicines and sieving medicines, simultaneously enriches the types of models of chronic pain experimental animals, and has important academic value and wide application prospects.

The invention relates to an establishment method and an application of a central post-stroke pain (CPSP) animal model and belongs to the technical field of animal model construction. The establishmentmethod comprises the step of injecting 0.1-0.3 U of VII-type collagenase into a right thalamic ventroposterior lateral nucleus of rat brain to obtain the CPSP animal model. With the adoption of the thalamic brain pain model established by stereo-position injection of VII-type collagenase into the dorsal thalamic ventroposterior lateral nucleus of a rat, pain characteristics of nervus centralis pathological thalamus pain are evaluated by detecting mechanical pain, heat pain, cold pain and biped balance pain; the emotional response of anxiety and forced swimming are evaluated by field experiments, and the depression state is evaluated by sweet water experiment; the occurrence and change condition of neuroinflammation reaction is evaluated by immunofluorescence and immunoblotting; a transmission electron microscope analyzes the ultrastructure change, screens the CPSP animal model and evaluates the neurobiology mechanism of behavioral features and occurrence and development of cerebral hemorrhage thalamus pain after stereo-position injection of VII-type collagenase.

The invention relates to an application of Akt IV in preparation of a medicine for relieving inflammatory pain. By intrathecally injecting three dosages of Akt IV into L5-L6 sacrum gap 30 min before injecting the BmK I, the relieving effects of different dosages of Akt IV in the phenomenon such as experimental spontaneous pain, paroxysmal pain sense grand mal, bilateral mechanical pain sensitive and unilateral heat pain sensitive are researched. The Akt IV is based on an experimental animal inflammatory pain model and a basis for researching the Akt signal pathway related analgesic molecular mechanism and developing a novel analgesic medicine is provided.

The invention provides application of pulsatilla saponin B5 or pharmaceutically acceptable salts, eutectic crystals, stereoisomers, prodrugs, solvates and metabolites thereof in preparation of drugs for preventing and / or treating pain, and the pulsatilla saponin B5 can significantly relieve the severity of neuropathic pain. For example, a mechanical pain threshold value caused by von Frey nylon fiber vertical stimulation or a crymodynia threshold value caused by acetone stimulation of a spinal nerve ligation model is improved, the effect is more excellent than that of conventionally used pregabalin, the economic burden of patients suffering from neuropathic pain and the society can be relieved, the life quality of the patients is improved, and the application prospect is wide. The method has great economic value and is suggested to be popularized and applied.

The invention discloses effect of connexin Panx1 in preparation of a medicine for preventing and treating neuropathic pain, and belongs to the technical field of biological medicines. Main expression Panx1 in Schwann cells is determined, and the expression quantity of the Panx1 can be remarkably increased due to chronic neuropathic pathological injury; an inhibitor and a mimic peptide of the Panx1 can remarkably inhibit mechanical pain and heat pain caused by chronic neuropathic pathological injury of sciatic nerves, and meanwhile, a Panx1 inhibitor probenecid can remarkably inhibit the expression of the Panx1 caused by injury. Therefore, powerful basic research evidence is provided for treating patients with chronic neuropathic pathological pain by clinically utilizing the Panx1 inhibitor in the future.

The present invention relates to the identification of Myo1a as a biomarker of conversion of acute pain into chronic pain, and as a therapeutic target. The invention in particular relates to products and methods for assessing the predisposition of a subject to develop an injury-induced chronic mechanical pain and / or an inflammatory-induced chronic thermal pain, and is particularly suited for mammals, preferably human subjects. The present invention more specifically relates to the assessment of the predisposition of a subject to develop an injury-induced chronic mechanical pain and / or an inflammatory-induced chronic thermal pain using preferably the MYO1A gene as a biomarker. Inventors herein provide binding reagents specific for MYO1A, compositions, devices, kits containing the same and animal model, and further describe their uses for assessing the predisposition of a subject to suffer from chronic pain. The invention also relates to products and methods for diagnosing, preventing, managing or treating chronic pain.

The invention relates to an application of a protein kinase B inhibitor in preparation of a medicine for relieving inflammatory pain. By intrathecally injecting three dosages of Akt IV into L5-L6 sacrum gap 30 min before injecting the BmK 1, the relieving effects of different dosages of Akt IV in the phenomenon such as experimental spontaneous pain, paroxysmal pain sense grand mal, bilateral mechanical pain sensitive and unilateral heat pain sensitive are researched. The protein kinase B inhibitor is built on an experimental animal inflammatory pain model and a basis for researching the Akt signal pathway related analgesic molecular mechanism and developing a novel analgesic medicine is provided.

The invention discloses an application of CDN1163 in preparation of a medicine for relieving or treating neuropathic pain, and the CDN1163 can act on neuropathic pain including one or more of central nervous pain and peripheral neuropathic pain, improves mechanical pain sensitivity and heat pain sensitivity caused by chronic sciatic nerve compression injury of rats, improves meuron shrinkage and astrocyte activation of lumbar intervertebral foramen 5 dorsal root ganglion, inhibits neuron excitability increase of lumbar intervertebral foramen 4-6 dorsal root ganglions, effectively relieves neuropathic pain symptoms, can remarkably reverse mechanical hyperalgesia and thermal hyperalgesia through repeated injection; no tolerance sign exists, after the medicine is stopped, the treatment effect can be maintained, and the CDN1163 is applied to preparation of medicines for relieving or treating neuropathic pain which is long in lasting time and difficult to treat.

The invention relates to a synthesis method of bufotenin and quaternary ammonium salt thereof. The method has the characteristics of simple steps, safe and convenient operation, high reaction efficiency, easy purification and separation, mild conditions and low cost, the total reaction yields of bufotenin and quaternary ammonium salt thereof are respectively greater than 65% and 60%, the purity ofthe synthesized product is high (greater than 99.0%), and the synthesis method is suitable for industrial production. A large number of experiments are carried out for screening, and heat pain and mechanical pain behavioral evaluation and phospholipidomics evaluation are combined to compare the activity of several tryptamine components, and the result shows that the bufotenin quaternary ammoniumsalt has the optimal analgesic effect, and also has a synergistic effect with morphine.